Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Screening for factor V Leiden mutation before prescribing combination oral contraceptives.

Fertility and sterility - 1 Oct 1999

Creinin M D, Lisman R, Strickler R C

Abstract excerpt

OBJECTIVE: To evaluate the cost-effectiveness of screening for factor V Leiden mutation in women in the United States who use combination oral contraceptives. DESIGN: Cost-effectiveness analysis. SETTING: A national research reference laboratory, a university medical center, and an academic health center managed care organization. PATIENT(S): Women of reproductive age in the United States. INTERVENTION(S):...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cost-Benefit Analysis
Share to Factor V
Share to Genetic Carrier Screening

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Genetic Testing

Share to Mutation

Share to Thromboembolism

Source

Identifiers

PMID: 10521103
DOI: 10.1016/s0015-0282(99)00318-0

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Screening for factor V Leiden mutation before prescribing combination oral contraceptives.PMID 10521103Read ↗

Factor V Leiden: should all women be screened prior to commencing the contraceptive pill?Semantic proximity Read ↗

Thrombotic risk during oral contraceptive use and pregnancy in women with factor V Leiden or prothrombin mutation: a rational approach to contraception.Semantic proximity Read ↗

Cost-effectiveness of screening and extended anticoagulation for carriers of both factor V Leiden and prothrombin G20210A.Semantic proximity Read ↗

Factor V Leiden: should we screen oral contraceptive users and pregnant women?Semantic proximity Read ↗

Testing for factor V Leiden in patients with pulmonary or venous thromboembolism: a cost-effectiveness analysis.Semantic proximity Read ↗

[Screening for factor V Leiden mutation in women using combined hormonal contraceptives or hormone replacement therapy].Semantic proximity Read ↗

Thrombosis risk with the use of hormonal contraception among women with thrombophilia: An updated systematic review.Semantic proximity Read ↗

Genetic screening for the predisposition to venous thromboembolism: a cost-utility analysis of clinical practice in the Italian health care system.Semantic proximity Read ↗

Extended anticoagulation for prevention of recurrent venous thromboembolism in carriers of factor V Leiden--cost-effectiveness analysis.Semantic proximity Read ↗

Genetic-guided pharmacotherapy for venous thromboembolism: a systematic and critical review of economic evaluations.Semantic proximity Read ↗

Economic evaluation of a novel genetic screening test for risk of venous thromboembolism compared with standard of care in women considering combined hormonal contraception in Switzerland.Semantic proximity Read ↗

Are factor V Leiden carriers who use oral contraceptives at extreme risk for venous thromboembolism?Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.